A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes
NCT ID: NCT02008851
Last Updated: 2014-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
1 participants
INTERVENTIONAL
2013-12-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Implantation of Neo-kidney Augment
Patients receiving one dose (implant) of NKA into the left kidney
Neo-kidney augment
Injection of 3.0 x 10e6 selected renal cells into the left kidney of the patient
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neo-kidney augment
Injection of 3.0 x 10e6 selected renal cells into the left kidney of the patient
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with CKD defined as glomerular filtration rate (GFR) of 20 - 50 mL/min/1.73m2, inclusive.
* Microalbuminuria that cannot be explained by an alternative diagnosis. Microalbuminuria is defined as a urinary albumin-creatinine ration (UACR) ≥ 30 mg/g or urine albumin excretion ≥ 30 mg/day on 24 hour urine collection.
* Ongoing treatment with ACEi or ARB. Patients who are intolerant may be included as long as they have stable blood pressure.
* Systolic blood pressure between 105 and 140 mmHg (inclusive) and diastolic blood pressure ≤ 90 mmHg.
* The patient should have historical data to provide a reasonable estimate of the rate of progression of CKD
Exclusion Criteria
* History of a renal transplant.
* HbA1c \> 10% at Screening.
* Hemoglobin levels \< 9 g/dL prior to biopsy or implant.
* Known allergy to kanamycin or structurally similar aminoglycoside antibiotics.
* Abnormal coagulation status as measured by activated partial prothrombin time, international normalized ratio (INR), and/or platelet count.
* Ineligible for a biopsy (e.g., based on size or cortical depth), MRI or renal scintigraphy study (e.g. due to hypersensitivity or allergy) according to standard site practices.
* Not a good candidate for laparoscopic surgical procedure (based on the assessment of the surgeon who will be performing the implant), including patients who are morbidly obese, have excessive fat surrounding the kidney, have a BMI \> 45, or who are otherwise at excessive risk for serious complications.
* Clinically significant infection requiring parenteral antibiotics within 6 weeks of biopsy or implantation.
* Patients with small kidneys (average size \< 9 cm) or only one kidney. Patients with a rapid decline in renal function over the last 3 months prior to biopsy or acute kidney injury.
* Patients with any of the following conditions prior to biopsy: renal tumors, polycystic kidney disease, renal cysts or other anatomic abnormalities that would interfere with the biopsy or implantation procedure (e.g., cysts in the pathway of the injection for implantation), hydronephrosis, skin infection over proposed biopsy sites, or evidence of a urinary tract infection.
* Female subjects who are pregnant, lactating (breast feeding) or planning a pregnancy during the course of the study.
* History of cancer within the past 3 years (excluding non-melanoma skin cancer and carcinoma in situ of the cervix).
* Life expectancy of less than 2 years.
* Any contraindication or known anaphylactic or severe systemic reaction to either human blood products or materials of animal (bovine, porcine) origin or anesthetic agents.
* Positive for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) assessed.
* Subjects with active tuberculosis (TB) requiring treatment in the past 3 years.
* Immunocompromised subjects or patients receiving immunosuppressive agents.
* Subjects with uncontrolled diabetes, incapacitating cardiac and/or pulmonary disorders.
* History of active alcohol and/or drug abuse that in the investigator's assessment would impair the subject's ability to comply with the protocol.
* Patients with clinically significant hepatic disease.
* Patients with bleeding disorders that would, in the opinion of the Investigator, interfere with the performance of study procedures; patients taking Coumarins (e.g.,Warfarin) or other anticoagulants (e.g. enoxaparin or direct thrombin inhibitors).
* Use of any investigational product within 3 months of the biopsy .
30 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tengion
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric McAllister, MD, DPhil
Role: STUDY_DIRECTOR
Tengion, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Chicago Medicine
Chicago, Illinois, United States
LSU Health Care Services
New Orleans, Louisiana, United States
Brigham & Women's Hospital
Boston, Massachusetts, United States
UNC Medical Center
Chapel Hill, North Carolina, United States
Vanderbilt University
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TNG-CL011
Identifier Type: -
Identifier Source: org_study_id